| Title | Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group |
| Authors | Liu, Weiping Yang, Yong Qi, Shunan Wang, Ying He, Xia Zhang, Liling Qu, Baolin Qian, Liting Hou, Xiaorong Qiao, Xueying Wang, Hua Li, Gaofeng Zhang, Yujing Zhu, Yuan Cao, Jianzhong Wu, Junxin Wu, Tao Zhu, Suyu Shi, Mei Xu, Liming Su, Hang Lin, Ningjing Zhu, Jun Li, Yexiong Song, Yuqin |
| Affiliation | Peking Univ, Dept Lymphoma, Dept Radiat Oncol,Canc Hosp & Inst, Key Lab Carcdnogenesis & Translationa Res,Minist, Beijing, Peoples R China Chinese Acad Med Sci CAMS, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China Peking Union Med Coll PUMC, Ctr Canc Precis Med, CAMS & PUMC, Natl Inst Biol Sci,Collaborat Innovat Ctr Canc Me, Beijing, Peoples R China Chongqing Univ, Dept Radiat Oncol, Canc Hosp, Chongqing, Peoples R China Chongqing Canc Hosp, Chongqing, Peoples R China Nanjing Med Univ, Dept Radiat Oncol, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China Chinese Peoples Liberat Army, Dept Radiat Oncol, Med Ctr 1, Gen Hosp, Beijing, Peoples R China Anhui Med Univ, Dept Radiat Oncol, Affiliated Prov Hosp, Hefei, Peoples R China Chinese Acad Med Sci CAMS, Peking Union Med Coll Hosp, Dept Radiat Oncol, Beijing, Peoples R China Peking Union Med Coll PUMC, Beijing, Peoples R China Hebei Med Univ, Dept Radiat Oncol, Hosp 4, Shijiazhuang, Hebei, Peoples R China Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Gerontol, Inst Geriatr Med,Dept Radiat Oncol, Beijing, Peoples R China Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China Zhejiang Canc Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China Shanxi Canc Hosp, Dept Radiat Oncol, Taiyuan, Peoples R China Shanxi Med Univ, Affiliated Canc Hosp, Taiyuan, Peoples R China Fujian Prov Canc Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China Guizhou Med Univ, Guizhou Canc Hosp, Dept Radiat Oncol, Affiliated Hosp, Guiyang, Peoples R China Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Peoples R China Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China Fourth Mil Med Univ, Dept Radiat Oncol, Xijing Hosp, Xian, Peoples R China Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Radiat Oncol, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China Chinese Peoples Liberat Army, Dept Lymphoma, Gen Hosp, Med Ctr 5, Beijing, Peoples R China |
| Issue Date | 19-Feb-2021 |
| Publisher | FRONTIERS IN ONCOLOGY |
| Abstract | Patients with advanced-stage natural killer/T-cell lymphoma (NKTCL) usually have a poor prognosis. However, there is limited data of comprehensive analysis on this particular patient population due to the rarity of the disease. The present study aimed to investigate the treatment models, survival outcomes, and prognosis of advanced-stage NKTCL. Data from 336 patients with advanced-stage NKTCL diagnosed between 2006 and 2015 in the China Lymphoma Collaborative Group database were retrospectively analyzed. The median age was 42 years and the male/female ratio was 2.4:1. About 97% of patients had stage IV disease and 77% had >1 extranodal involvement site. All patients received chemotherapy, with the most common option being asparaginase (Asp)-containing regimens (n=146; 43.5%). Among 286 patients with available response data, the overall response rate (ORR) was 57.3% with a complete remission (CR) rate of 35.7%. Asp-containing regimens led to better ORRs (86/132, 65.2% vs. 54/113, 47.8%, P = 0.006) and CR rates (60/132, 45.5% vs. 27/113, 23.9%, P < 0.001) than non-Asp-containing regimens. The expected 5-year progression-free survival (PFS) and overall survival (OS) rates were 22.6 and 32.0%, respectively, for the whole cohort. Compared to non-Asp-containing chemotherapy, Asp-containing chemotherapy improved 5-year PFS (34.2 vs. 17.1%, P < 0.001) and OS (45.3 vs. 27.8%, P < 0.001). A trend toward improvement in OS was observed when gemcitabine was added to Asp-containing chemotherapies. Moreover, those undergoing autologous hematopoietic stem cell transplantation had prolonged survival time. In conclusion, Asp-containing chemotherapy could improve the prognosis of advanced-stage NKTCL, and refinement of treatment models is warranted in the future. |
| URI | http://hdl.handle.net/20.500.11897/605863 |
| ISSN | 2234-943X |
| DOI | 10.3389/fonc.2020.583050 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 |
